GastroAGI Logo
OverviewBlogsAbout
Trending TopicsConference
Topics/Endoscopy/EUS-Guided Gallbladder vs Bile Duct Drainage for Malignant Biliary Obstruction: Multicenter Trial

EUS-Guided Gallbladder vs Bile Duct Drainage for Malignant Biliary Obstruction: Multicenter Trial

Clinical knowledge base curated and reviewed by GastroAGI TeamLast updated December 1, 2025

Quick Answer

The study you are referring to is an international multicenter trial that compared two endoscopic ultrasound (EUS)-guided procedures for managing distal malignant biliary obstruction (MBO): EUS-guided gallbladder drainage (EUS-GBD) and EUS-guided choledochoduodenostomy (EUS-CDS). Traditionally, such conditions are managed using endoscopic retrograde cholangiopancreatography (ERCP), but this study explored alternative primary drainage strategies using EUS-guided techniques with lumen-apposing metal stents.


The study you are referring to is an international multicenter trial that compared two endoscopic ultrasound (EUS)-guided procedures for managing distal malignant biliary obstruction (MBO): EUS-guided gallbladder drainage (EUS-GBD) and EUS-guided choledochoduodenostomy (EUS-CDS). Traditionally, such conditions are managed using endoscopic retrograde cholangiopancreatography (ERCP), but this study explored alternative primary drainage strategies using EUS-guided techniques with lumen-apposing metal stents.

### Key Details of the Study:

1. **Study Design**:

  • Retrospective observational trial conducted across 28 tertiary care centers.
  • Timeframe: April 2017 to August 2024.

2. **Participants**:

  • A total of 291 patients with distal malignant biliary obstruction were included.
  • The majority of cases (84%) were due to pancreatic cancer.
  • 82 patients underwent EUS-GBD, while 209 underwent EUS-CDS.

3. **Methodology**:

  • To minimize selection bias, the study employed 1-to-1 propensity score matching, resulting in 154 matched patients (77 in each group).
  • Both procedures utilized lumen-apposing metal stents.

4. **Outcomes Compared**:

  • **Primary Outcome**: Clinical success (defined as effective biliary drainage and resolution of symptoms).
  • **Secondary Outcomes**: Technical success, adverse events, and overall survival.

### Results:

1. **Technical Success**:

  • EUS-GBD: 96%.
  • EUS-CDS: 99%.
  • Both procedures showed high and comparable rates of technical success.

2. **Clinical Success**:

  • Clinical success rates were similar between the two groups.

3. **Adverse Events**:

  • Both procedures had comparable adverse event profiles, indicating similar levels of safety.

4. **Overall Survival**:

  • No significant difference in overall survival was observed between the two groups.

### Conclusion:

The study concluded that EUS-GBD is a viable and effective alternative to EUS-CDS as a first-line therapy for distal malignant biliary obstruction. Both approaches demonstrated high technical and clinical success rates, comparable safety profiles, and similar survival outcomes. This suggests that the choice between EUS-GBD and EUS-CDS can be guided by factors such as anatomical considerations, operator expertise, and patient-specific characteristics.

### Implications:

This trial supports the use of EUS-guided procedures as effective alternatives to ERCP in managing distal MBO. The findings reinforce the flexibility in choosing between EUS-GBD and EUS-CDS, allowing clinicians to tailor their approach to the individual needs of the patient.

Related Q&A

Duodenal Mucosal Resurfacing REMAIN-1 Study: DDW | 2026

Introduction: Obesity has become one of the greatest global health challenges. New incretin-based therapies—including semaglutide, tirzepatide, resmetirom, and SGLT2 inhibitors such as empagliflozin—have transformed the treatment of obesity, diabetes, and MASLD. However, many patients discontinue...

EUS-FNAB for Solid Pancreatic Lesions: GIE | July 2026

Introduction: Endoscopic ultrasound-guided fine-needle biopsy (EUS-FNB) is the standard technique for diagnosing solid pancreatic lesions. Traditionally, biopsy specimens are processed for cytology, often requiring on-site cytopathology support. This multicenter prospective study evaluated whether directly placing...

Durable Endoscopic Partial Reversal of Roux-en-Y Gastric Bypass Using Parallel LAMS Septotomy: GIE | July 2026

Introduction: Although Roux-en-Y gastric bypass (RYGB) is an effective bariatric procedure, a small proportion of patients develop severe nutritional complications, refractory dumping syndrome, or other debilitating adverse events requiring reversal. This study describes a novel...

EUS Double Drainage for Malignant Dual Obstruction : Gut | Jul 2026

Introduction: Simultaneous malignant distal biliary obstruction (MDBO) and gastric outlet obstruction (GOO), commonly caused by advanced pancreatic, biliary, or duodenal cancers, presents a major palliative challenge. Conventional endoscopic approaches often require repeated interventions and may...

Endoscopic Mucosal and Submucosal Cutting in benign esophageal stricture: Gut | July 2026

Introduction: Long benign esophageal strictures remain one of the most difficult benign conditions to manage. Although endoscopic dilation and incision techniques provide temporary relief, recurrence is common, often requiring repeated interventions. This study introduces a...

Economic Impact of POEM and ESD: GIE | June 2026

Introduction: Peroral endoscopic myotomy (POEM) and endoscopic submucosal dissection (ESD) have revolutionized the management of esophageal motility disorders and early gastrointestinal neoplasia. Despite their proven clinical benefits, widespread adoption has been limited by concerns regarding...

GastroAGI Logo

We are pioneers in clinical intelligence, dedicated to helping gastroenterologists harness the power of artificial intelligence to drive precision, efficiency, and patient growth.

For You

For StudentsFor CliniciansFor ResearchersSoonFor Patients

Core Tools

MELD-Na ScoreChild-PughFIB-4 IndexGlasgow-BlatchfordBISAP Score

Explore

OverviewAboutCalculators
Trending Topics
Conference Briefings
Blog Insights
©GastroAGI 2026
Privacy PolicyTerms of UseMedical Disclaimer